EMERGENCY contraceptives
containing levonorgestrel or
ulipristal acetate remain suitable
for women of all body weights in
preventing pregnancy, following
a review by the Committee for
Medicinal Products for Human
Use, which recommended that
these could be used, as the
benefits outweighed the risks
with effectiveness not significantly
impaired by excess body weight.
An EU-wide review was prompted
by changes to product information
for Norlevo in 2013 on the basis of
results from two clinical studies,
which stated it was less effective
in women weighing 75kg and not
effective in women weighing 80kg
or more (PD 03 Mar).
The Therapeutic Goods
Administration said it was aware
of the EMA’s recommendation
and that its review, which was
“almost complete”, would include
consideration of this finding.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jul 14
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.